Former heavyweight champion Joseph Parker has maintained that a recent positive drug test, which led to his provisional suspension from boxing, was the result of indirect exposure to cocaine through his nutritionist, according to a statement from UK Anti-Doping (UKAD). The New Zealand-born fighter tested positive for benzoylecgonine, a primary metabolite of cocaine, after a routine anti‑doping control conducted shortly after his unexpected loss to Britain’s Fabio Wardley on 25 October 2025. Parker has consistently denied ever ingesting a prohibited substance, and on Wednesday he announced that the suspension—potentially lasting up to two years—had been lifted, promising a swift return to the ring.
UKAD confirmed on Thursday that Parker was cleared to resume his boxing career, releasing details of the investigation that included the 34‑year‑old’s explanation for the adverse analytical finding (AAF). The governing body’s statement explained that on 6 March 2026 Parker supplied evidence claiming the AAF stemmed from exposure to cocaine used by the nutritionist he had hired in preparation for the Wardley bout.
According to Parker, the nutritionist admitted to being a regular cocaine user and said he had taken the drug daily during the week leading up to the fight. Further inquiries were made by UKAD between 14 April and 3 June 2026, during which Parker clarified that he had first begun working with this nutritionist in April 2023. The anti‑doping authority noted that, after a thorough review, it decided to impose a three‑month period of ineligibility, which it considered already served, because an independent scientific expert concluded that any cocaine ingestion had occurred out of competition and therefore bore no connection to Parker’s sporting performance. The expert’s opinion, received by UKAD on 15 June 2026, indicated that Parker’s cocaine exposure most likely took place before 11:59 p.m.
on 24 October 2025, i.e., outside the competition window. On 22 June 2026 UKAD communicated to Parker that, based on the expert’s assessment, the ingestion was out‑of‑competition and unrelated to his athletic activity. Consequently, the provisional suspension was lifted immediately, and a three‑month sanction was deemed served as the final penalty for the anti‑doping rule violation.
The scientific consultant also entertained the possibility that the benzoylecgonine detected in Parker’s urine could have resulted from contamination rather than intentional use. The expert stated that the cocaine might have entered Parker’s system orally via food or supplements tainted by his nutritionist’s cocaine habit.
Nevertheless, the expert could not completely rule out that the metabolite was the residual effect of a larger, pharmacologically active dose of cocaine. With the suspension lifted, the outcome of Parker’s fight against Wardley is being retroactively altered.
The 11th‑round stoppage, originally recorded as a knockout loss for Parker, will now be listed as a defeat by disqualification because of the anti‑doping violation. This adjustment has significant implications for Parker’s record and his standing in the heavyweight division.
Parker’s career trajectory provides context for the stakes involved. He first captured a world title in 2018 when he defeated Anthony Joshua, a victory that catapulted him into the global spotlight. After a setback against Joe Joyce in 2022, Parker rebounded impressively, stringing together six consecutive wins, including high‑profile victories over former champion Deontay Wilder and Chinese contender Zhilei Zhang. Those successes earned him the WBO interim heavyweight belt and positioned him as a mandatory challenger for the undisputed champion Oleksandr Usyk.
A highly anticipated showdown with then‑IBF champion Daniel Dubois was slated for February 2026, but Dubois fell ill shortly before the fight, leading to its cancellation. Undeterred, Parker chose to risk his mandatory challenger status by taking the fight against Wardley, hoping to maintain momentum and stay on the path toward a title shot.
Unfortunately, the bout ended in defeat, and the subsequent doping controversy has added a further layer of complexity to his comeback plans. Looking ahead, Parker’s team says the boxer is eager to get back in training and is already exploring potential matchups for late 2026 or early 2027.
The lifted suspension means he can compete in sanctioned events without restriction, but the disqualification loss will remain on his record, potentially affecting his ranking and future title opportunities. Analysts suggest that Parker will likely need to secure a decisive win against a ranked opponent to re‑establish his claim as a top‑contender and to convince promoters that he remains a viable draw for major fights. The broader anti‑doping community has taken note of this case as an illustration of the complexities surrounding indirect drug exposure.
While the primary purpose of anti‑doping regulations is to ensure a level playing field, scenarios like Parker’s highlight the challenges of attributing responsibility when a third party’s illicit behavior contaminates an athlete’s sample. UKAD’s decision to impose a reduced sanction, acknowledging the out‑of‑competition nature of the exposure, may set a precedent for future cases where athletes claim inadvertent contamination through support staff.
In summary, Joseph Parker’s positive test for benzoylecgonine has been officially attributed to exposure from his nutritionist’s cocaine use, leading to a provisional suspension that was lifted after an expert determined the ingestion occurred outside competition. The three‑month sanction is considered served, and Parker’s disqualification loss to Wardley will stand on his record.
With his eligibility restored, Parker is poised to resume his pursuit of heavyweight glory, though he must now navigate the repercussions of a tarnished result and the need to rebuild his standing in a highly competitive division.